A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
Highlights • We reported the application of icotinib in the routine clinical setting. • Favorable tolerability of icotinib was seen in overall population and elder patients. • Icotinib displayed antitumor activities in unselected patients. • More efficacy benefits were documented in EGFR-mutant pati...
Saved in:
Published in | Lung cancer (Amsterdam, Netherlands) Vol. 86; no. 2; pp. 207 - 212 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Ireland Ltd
01.11.2014
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Highlights • We reported the application of icotinib in the routine clinical setting. • Favorable tolerability of icotinib was seen in overall population and elder patients. • Icotinib displayed antitumor activities in unselected patients. • More efficacy benefits were documented in EGFR-mutant patients. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0169-5002 1872-8332 |
DOI: | 10.1016/j.lungcan.2014.08.014 |